206 related articles for article (PubMed ID: 16639364)
1. Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG).
Hofbauer LC
Ann Endocrinol (Paris); 2006 Apr; 67(2):139-41. PubMed ID: 16639364
[No Abstract] [Full Text] [Related]
2. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.
Hofbauer LC; Schoppet M
JAMA; 2004 Jul; 292(4):490-5. PubMed ID: 15280347
[TBL] [Abstract][Full Text] [Related]
3. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
Kostenuik PJ
Curr Opin Pharmacol; 2005 Dec; 5(6):618-25. PubMed ID: 16188502
[TBL] [Abstract][Full Text] [Related]
4. Anti-RANKL therapy for inflammatory bone disorders: Mechanisms and potential clinical applications.
Anandarajah AP; Schwarz EM
J Cell Biochem; 2006 Feb; 97(2):226-32. PubMed ID: 16240334
[TBL] [Abstract][Full Text] [Related]
5. [Osteoprotegerin--a neutralizing receptor, protector of bones and a potential antiresorptive agent].
Andelković Z; Katić V; Mihajlović D; Zivković V; Petrović A; Lalosević D
Med Pregl; 2005; 58(7-8):362-7. PubMed ID: 16296579
[TBL] [Abstract][Full Text] [Related]
6. Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.
Aubin JE; Bonnelye E
Medscape Womens Health; 2000 Mar; 5(2):5. PubMed ID: 10792853
[TBL] [Abstract][Full Text] [Related]
7. [Clinical implications of new insights into the regulation of bone resorption].
Lems WF; Bijlsma JW
Ned Tijdschr Geneeskd; 2005 Jul; 149(30):1664-7. PubMed ID: 16104110
[TBL] [Abstract][Full Text] [Related]
8. Osteoprotegerin, RANK, RANKL.
Stejskal D; Bartek J; Pastorková R; Růzicka V; Oral I; Horalík D
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2001 Dec; 145(2):61-4. PubMed ID: 12426773
[TBL] [Abstract][Full Text] [Related]
9. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system.
Tanaka S; Nakamura K; Takahasi N; Suda T
Immunol Rev; 2005 Dec; 208():30-49. PubMed ID: 16313339
[TBL] [Abstract][Full Text] [Related]
10. Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo.
Cheng X; Kinosaki M; Takami M; Choi Y; Zhang H; Murali R
J Biol Chem; 2004 Feb; 279(9):8269-77. PubMed ID: 14679212
[TBL] [Abstract][Full Text] [Related]
11. The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.
Yeung RS
J Rheumatol; 2004 May; 31(5):844-6. PubMed ID: 15124240
[No Abstract] [Full Text] [Related]
12. [Molecular mechanism of bone metabolism].
Kotake S; Utagawa N; Suda T; Kamatani N
Nihon Naika Gakkai Zasshi; 2000 Oct; 89(10):2046-53. PubMed ID: 11215116
[No Abstract] [Full Text] [Related]
13. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor-{kappa}B (RANK) ligand/RANK system.
Liu XH; Kirschenbaum A; Yao S; Levine AC
Endocrinology; 2005 Apr; 146(4):1991-8. PubMed ID: 15618359
[TBL] [Abstract][Full Text] [Related]
14. [Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?].
Ferrer Cañabate J; Tovar I; Martínez P
An Med Interna; 2002 Aug; 19(8):385-88. PubMed ID: 12244784
[No Abstract] [Full Text] [Related]
15. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint.
Haynes DR; Crotti TN; Loric M; Bain GI; Atkins GJ; Findlay DM
Rheumatology (Oxford); 2001 Jun; 40(6):623-30. PubMed ID: 11426018
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.
Kostenuik PJ; Shalhoub V
Curr Pharm Des; 2001 May; 7(8):613-35. PubMed ID: 11375772
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption.
Aubin JE; Bonnelye E
Osteoporos Int; 2000; 11(11):905-13. PubMed ID: 11193242
[TBL] [Abstract][Full Text] [Related]
18. Osteoprotegerin-receptor activator of nuclear factor-kappaB ligand ratio: a new approach to osteoporosis treatment?
Coetzee M; Kruger MC
South Med J; 2004 May; 97(5):506-11. PubMed ID: 15180028
[TBL] [Abstract][Full Text] [Related]
19. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function.
Schoppet M; Preissner KT; Hofbauer LC
Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):549-53. PubMed ID: 11950689
[TBL] [Abstract][Full Text] [Related]
20. [Recent advance in basic research for osteoporosis].
Suda T; Miyaura C
Nihon Rinsho; 2004 Feb; 62 Suppl 2():13-20. PubMed ID: 15035090
[No Abstract] [Full Text] [Related]
[Next] [New Search]
